Base de dados : MEDLINE
Pesquisa : D02.092.831.690 [Categoria DeCS]
Referências encontradas : 2237 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 224 ir para página                         

  1 / 2237 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28445845
[Au] Autor:Mináriková M; Fojtikova V; Vyskocilová E; Sedlácek J; Sikut M; Borek-Dohalska L; Stiborová M; Martinkova M
[Ad] Endereço:Department of Biochemistry, Faculty of Science, Charles University, Hlavova (Albertov) 2030-8, Prague 2, Czech Republic.
[Ti] Título:The capacity and effectiveness of diosmectite and charcoal in trapping the compounds causing the most frequent intoxications in acute medicine: A comparative study.
[So] Source:Environ Toxicol Pharmacol;52:214-220, 2017 Jun.
[Is] ISSN:1872-7077
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The aim of the study was to compare the adsorption ability of two adsorbent materials, namely diosmectite and activated charcoal towards selected model compounds that are most commonly involved in acute intoxication. Eleven model compounds were selected: acetylsalicylic acid, α-amanitin, amlodipine, digoxin, phenobarbital, ibuprofen, imipramine, carbamazepine, oxazepam, promethazine, and theophylline. Of the tested compounds, promethazine and imipramine were the most effectively adsorbed to diosmectite. Their adsorption to diosmectite (0.356±0.029mg promethazine/mg diosmectite and 0.354±0.019mg imipramine/mg diosmectite, respectively) was significantly higher than their adsorption to activated charcoal. The effect of temperature and pH on the adsorption efficiencies was also evaluated. In the case of experiments with mixture of both adsorbents, they mostly behaved in a solution independently or in a slightly antagonistic way. Using various methods such as N adsorption and thermogravimetric analysis, the structure and texture of diosmectite and activated charcoal were attained.
[Mh] Termos MeSH primário: Antídotos/química
Carvão Vegetal/química
Envenenamento/prevenção & controle
Silicatos/química
[Mh] Termos MeSH secundário: Adsorção
Alfa-Amanitina/química
Anlodipino/química
Aspirina/química
Carbamazepina/química
Digoxina/química
Ibuprofeno/química
Imipramina/química
Oxazepam/química
Fenobarbital/química
Prometazina/química
Teofilina/química
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alpha-Amanitin); 0 (Antidotes); 0 (Silicates); 16291-96-6 (Charcoal); 1J444QC288 (Amlodipine); 33CM23913M (Carbamazepine); 6GOW6DWN2A (Oxazepam); 73K4184T59 (Digoxin); A3N5ZCN45C (Smectite); C137DTR5RG (Theophylline); FF28EJQ494 (Promethazine); OGG85SX4E4 (Imipramine); R16CO5Y76E (Aspirin); WK2XYI10QM (Ibuprofen); YQE403BP4D (Phenobarbital)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE


  2 / 2237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Sidrim, José Júlio Costa
Rocha, Marcos Fábio Gadelha
Texto completo
[PMID]:27936915
[Au] Autor:Sidrim JJ; Vasconcelos DC; Riello GB; Guedes GM; Serpa R; Bandeira TJ; Monteiro AJ; Cordeiro RA; Castelo-Branco DS; Rocha MF; Brilhante RS
[Ad] Endereço:a Specialized Center of Medical Micology , Federal University of Ceará , Fortaleza , Brazil.
[Ti] Título:Promethazine improves antibiotic efficacy and disrupts biofilms of Burkholderia pseudomallei.
[So] Source:Biofouling;33(1):88-97, 2017 Jan.
[Is] ISSN:1029-2454
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Efflux pumps are important defense mechanisms against antimicrobial drugs and maintenance of Burkholderia pseudomallei biofilms. This study evaluated the effect of the efflux pump inhibitor promethazine on the structure and antimicrobial susceptibility of B. pseudomallei biofilms. Susceptibility of planktonic cells and biofilms to promethazine alone and combined with antimicrobials was assessed by the broth microdilution test and biofilm metabolic activity was determined with resazurin. The effect of promethazine on 48 h-grown biofilms was also evaluated through confocal and electronic microscopy. The minimum inhibitory concentration (MIC) of promethazine was 780 mg l , while the minimum biofilm elimination concentration (MBEC) was 780-3,120 mg l . Promethazine reduced the MIC values for erythromycin, trimethoprim/sulfamethoxazole, gentamicin and ciprofloxacin and reduced the MBEC values for all tested drugs (p<0.05). Microscopic analyses demonstrated that promethazine altered the biofilm structure of B. pseudomallei, even at subinhibitory concentrations, possibly facilitating antibiotic penetration. Promethazine improves antibiotics efficacy against B. pseudomallei biofilms, by disrupting biofilm structure.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Biofilmes/efeitos dos fármacos
Burkholderia pseudomallei/efeitos dos fármacos
Prometazina/farmacologia
[Mh] Termos MeSH secundário: Burkholderia pseudomallei/fisiologia
Sinergismo Farmacológico
Testes de Sensibilidade Microbiana
Plâncton/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); FF28EJQ494 (Promethazine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161213
[St] Status:MEDLINE
[do] DOI:10.1080/08927014.2016.1262846


  3 / 2237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27288889
[Au] Autor:Jensen LL; Rømsing J; Dalhoff K
[Ad] Endereço:Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
[Ti] Título:A Danish Survey of Antihistamine Use and Poisoning Patterns.
[So] Source:Basic Clin Pharmacol Toxicol;120(1):64-70, 2017 Jan.
[Is] ISSN:1742-7843
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The first-generation antihistamine, promethazine, became a prescription-only drug in Denmark as of December 2014. First-generation antihistamines are known to have a higher toxic potential than second-generation antihistamines. The aim of this study was to provide a nationwide description of the antihistamine use and poisoning pattern from 2007 to 2013 in Denmark based on two independent databases. There were 1049 antihistamine exposures in the national, advisory telephone service specialized in poisonings, the Danish Poison and Information Centre (DPIC), and 456 exposures in the three registers used within the State Serum Institute of Denmark (SSI), a department under the Danish Ministry of Health dealing with research-based health surveillance in Denmark. First-generation antihistamines constitute 61% and 73% of antihistamine registrations in DPIC and SSI, respectively. Antihistamine exposures increased by 7 exposures/10,000 enquiries per year in DPIC and six admissions per year in SSI - this increase is not significant due to a sudden decrease in 2012. Intentional exposures constituted 65% in DPIC of which 82% was due to suicide attempts, and 78% of the involved antihistamines were first-generation antihistamines. Accidental exposures constituted 33% of which 61% were due to play and 29% involved first-generation antihistamines. Single antihistamine exposures constituted 65% of DPIC exposures of which 98% involved only one brand of antihistamine. Multidrug exposures constituted 35% of DPIC exposures with equally distributed coingestants. Hospitalization was recommended in 78% of DPIC exposures. Admissions required only 1-day of treatment in 91% of the SSI exposures. One of the 14 identified deaths in the SSI study population was directly related to antihistamine poisoning. Results support the limited disclosure of promethazine in Denmark and illustrate a generation-specific pattern indicating a suspected replacement of promethazine with other first-generation antihistamines.
[Mh] Termos MeSH primário: Overdose de Drogas/etiologia
Antagonistas dos Receptores Histamínicos/envenenamento
Antagonistas dos Receptores Histamínicos H1/envenenamento
Prometazina/envenenamento
[Mh] Termos MeSH secundário: Fatores Etários
Dinamarca
Monitoramento de Medicamentos
Overdose de Drogas/mortalidade
Overdose de Drogas/terapia
Quimioterapia Combinada/efeitos adversos
Feminino
Pesquisas sobre Serviços de Saúde
Antagonistas dos Receptores Histamínicos/efeitos adversos
Antagonistas dos Receptores Histamínicos/uso terapêutico
Antagonistas dos Receptores Histamínicos H1/efeitos adversos
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Hospitalização
Seres Humanos
Tempo de Internação
Masculino
Centros de Controle de Intoxicações
Padrões de Prática Médica
Prometazina/efeitos adversos
Prometazina/uso terapêutico
Vigilância em Saúde Pública
Sistema de Registros
Estudos Retrospectivos
Medição de Risco
Tentativa de Suicídio
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histamine Antagonists); 0 (Histamine H1 Antagonists); FF28EJQ494 (Promethazine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170208
[Lr] Data última revisão:
170208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160612
[St] Status:MEDLINE
[do] DOI:10.1111/bcpt.12632


  4 / 2237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27885664
[Au] Autor:Huf G; Alexander J; Gandhi P; Allen MH
[Ad] Endereço:National Institute of Quality Control in Health, Oswaldo Cruz Foundation, Av. Brasil 4365, Manguinhos, Rio de Janeiro, Brazil, 21040-9000.
[Ti] Título:Haloperidol plus promethazine for psychosis-induced aggression.
[So] Source:Cochrane Database Syst Rev;11:CD005146, 2016 11 25.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Health services often manage agitated or violent people, and such behaviour is particularly prevalent in emergency psychiatric services (10%). The drugs used in such situations should ensure that the person becomes calm swiftly and safely. OBJECTIVES: To examine whether haloperidol plus promethazine is an effective treatment for psychosis-induced aggression. SEARCH METHODS: On 6 May 2015 we searched the Cochrane Schizophrenia Group's Register of Trials, which is compiled by systematic searches of major resources (including MEDLINE, EMBASE, AMED, BIOSIS, CINAHL, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings. SELECTION CRITERIA: All randomised clinical trials with useable data focusing on haloperidol plus promethazine for psychosis-induced aggression. DATA COLLECTION AND ANALYSIS: We independently extracted data. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI), on an intention-to-treat basis. For continuous data, we estimated the mean difference (MD) between groups and its 95% CI. We employed a fixed-effect model for analyses. We assessed risk of bias for included studies and created 'Summary of findings' tables using GRADE. MAIN RESULTS: We found two new randomised controlled trials (RCTs) from the 2015 update searching. The review now includes six studies, randomising 1367 participants and presenting data relevant to six comparisons.When haloperidol plus promethazine was compared with haloperidol alone for psychosis-induced aggression for the outcome not tranquil or asleep at 30 minutes, the combination treatment was clearly more effective (n=316, 1 RCT, RR 0.65, 95% CI 0.49 to 0.87, high-quality evidence). There were 10 occurrences of acute dystonia in the haloperidol alone arm and none in the combination group. The trial was stopped early as haloperidol alone was considered to be too toxic.When haloperidol plus promethazine was compared with olanzapine, high-quality data showed both approaches to be tranquillising. It was suggested that the combination of haloperidol plus promethazine was more effective, but the difference between the two approaches did not reach conventional levels of statistical significance (n=300, 1 RCT, RR 0.60, 95% CI 0.22 to 1.61, high-quality evidence). Lower-quality data suggested that the risk of unwanted excessive sedation was less with the combination approach (n=116, 2 RCTs, RR 0.67, 95% CI 0.12 to 3.84).When haloperidol plus promethazine was compared with ziprasidone all data were of lesser quality. We identified no binary data for the outcome tranquil or asleep. The average sedation score (Ramsay Sedation Scale) was lower for the combination approach but not to conventional levels of statistical significance (n=60, 1 RCT, MD -0.1, 95% CI - 0.58 to 0.38). These data were of low quality and it is unclear what they mean in clinical terms. The haloperidol plus promethazine combination appeared to cause less excessive sedation but again the difference did not reach conventional levels of statistical significance (n=111, 2 RCTs, RR 0.30, 95% CI 0.06 to 1.43).We found few data for the comparison of haloperidol plus promethazine versus haloperidol plus midazolam. Average Ramsay Sedation Scale scores suggest the combination of haloperidol plus midazolam to be the most sedating (n=60, 1 RCT, MD - 0.6, 95% CI -1.13 to -0.07, low-quality evidence). The risk of excessive sedation was considerably less with haloperidol plus promethazine (n=117, 2 RCTs, RR 0.12, 95% CI 0.03 to 0.49, low-quality evidence). Haloperidol plus promethazine seemed to decrease the risk of needing restraints by around 12 hours (n=60, 1 RCT, RR 0.24, 95% CI 0.10 to 0.55, low-quality evidence). It may be that use of midazolam with haloperidol sedates swiftly, but this effect does not last long.When haloperidol plus promethazine was compared with lorazepam, haloperidol plus promethazine seemed to more effectively cause sedation or tranquillisation by 30 minutes (n=200, 1 RCT, RR 0.26, 95% CI 0.10 to 0.68, high-quality evidence). The secondary outcome of needing restraints or seclusion by 12 hours was not clearly different between groups, with about 10% in each group needing this intrusive intervention (moderate-quality evidence). Sedation data were not reported, however, the combination group did have less 'any serious adverse event' in 24-hour follow-up, but there were not clear differences between the groups and we are unsure exactly what the adverse effect was. There were no deaths.When haloperidol plus promethazine was compared with midazolam, there was clear evidence that midazolam is more swiftly tranquillising of an aggressive situation than haloperidol plus promethazine (n=301, 1 RCT, RR 2.90, 95% CI 1.75 to 4.8, high-quality evidence). On its own, midazolam seems to be swift and effective in tranquillising people who are aggressive due to psychosis. There was no difference in risk of serious adverse event overall (n=301, 1 RCT, RR 1.01, 95% CI 0.06 to 15.95, high-quality evidence). However, 1 in 150 participants allocated haloperidol plus promethazine had a swiftly reversed seizure, and 1 in 151 given midazolam had swiftly reversed respiratory arrest. AUTHORS' CONCLUSIONS: Haloperidol plus promethazine is effective and safe, and its use is based on good evidence. Benzodiazepines work, with midazolam being particularly swift, but both midazolam and lorazepam cause respiratory depression. Olanzapine intramuscular and ziprasidone intramuscular do seem to be viable options and their action is swift, but resumption of aggression with subsequent need to re-inject was more likely than with haloperidol plus promethazine. Haloperidol used on its own without something to offset its frequent and serious adverse effects does seem difficult to justify.
[Mh] Termos MeSH primário: Agressão/efeitos dos fármacos
Haloperidol/uso terapêutico
Prometazina/uso terapêutico
Transtornos Psicóticos/tratamento farmacológico
[Mh] Termos MeSH secundário: Agressão/psicologia
Benzodiazepinas/uso terapêutico
Quimioterapia Combinada
Seres Humanos
Lorazepam/uso terapêutico
Midazolam/uso terapêutico
Agitação Psicomotora
Transtornos Psicóticos/psicologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Restrição Física/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
12794-10-4 (Benzodiazepines); FF28EJQ494 (Promethazine); J6292F8L3D (Haloperidol); O26FZP769L (Lorazepam); R60L0SM5BC (Midazolam)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170111
[Lr] Data última revisão:
170111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161126
[St] Status:MEDLINE


  5 / 2237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27725018
[Au] Autor:Abulfathi AA; Greyling T; Makiwane M; Esser M; Decloedt E
[Ad] Endereço:Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa. aaabulfathi@sun.ac.za.
[Ti] Título:Angio-oedema associated with colistin.
[So] Source:S Afr Med J;106(10):990-991, 2016 Sep 04.
[Is] ISSN:0256-9574
[Cp] País de publicação:South Africa
[La] Idioma:eng
[Ab] Resumo:A 50-year-old woman known to have type 1 diabetes mellitus presented with a rare case of angio-oedema associated with colistin use. The angio-oedema was temporally associated with the use and discontinuation of colistin with the reasonable exclusion of important differential diagnoses. Pseudoallergy may be a probable underlying mechanism. However, we cannot exclude the possibility of hereditary angio-oedema type 2 or 3, or that her concomitant medications (particularly enalapril) and her renal impairment contributed to the risk and severity of her angio-oedema.
[Mh] Termos MeSH primário: Angioedema
Colistina/efeitos adversos
Hidrocortisona/administração & dosagem
Prometazina/administração & dosagem
Sepse/tratamento farmacológico
Infecções Urinárias/complicações
[Mh] Termos MeSH secundário: Acinetobacter baumannii/isolamento & purificação
Angioedema/induzido quimicamente
Angioedema/diagnóstico
Angioedema/fisiopatologia
Angioedema/terapia
Antialérgicos/administração & dosagem
Antibacterianos/administração & dosagem
Antibacterianos/efeitos adversos
Colistina/administração & dosagem
Diagnóstico Diferencial
Feminino
Seres Humanos
Meia-Idade
Sepse/diagnóstico
Sepse/etiologia
Resultado do Tratamento
Infecções Urinárias/microbiologia
Suspensão de Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Anti-Bacterial Agents); FF28EJQ494 (Promethazine); WI4X0X7BPJ (Hydrocortisone); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170706
[Lr] Data última revisão:
170706
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161012
[St] Status:MEDLINE
[do] DOI:10.7196/SAMJ.2016.v106i10.10835


  6 / 2237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27531858
[Au] Autor:Naicker P; Anoopkumar-Dukie S; Grant GD; Neumann DL; Kavanagh JJ
[Ad] Endereço:Menzies Health Institute, Griffith University, Gold Coast, Queensland, Australia; School of Pharmacy, Griffith University, Gold Coast, Queensland, Australia.
[Ti] Título:Central cholinergic pathway involvement in the regulation of pupil diameter, blink rate and cognitive function.
[So] Source:Neuroscience;334:180-190, 2016 Oct 15.
[Is] ISSN:1873-7544
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Anticholinergic medications can exert their effects by acting on muscarinic receptors, which mediates the function of acetylcholine in the central nervous system. Acetylcholine plays a number of roles, particularly in regard to the control of muscle activity and normal cognitive functioning. Eighteen subjects were recruited into the human, double-blind, placebo-controlled, four-way crossover study. Pupil diameter and blink rate were assessed at rest while eye tracking technology recorded eye characteristics. Thereafter a cognitive task was performed, where pupil size and blink rate were once again measured. Assessments were performed pre-ingestion, 0.5h and 2h following the ingestion of a strong centrally acting anticholinergic (promethazine hydrochloride), a moderate centrally acting anticholinergic (hyoscine hydrobromide), an anticholinergic devoid of central effects (hyoscine butylbromide) and placebo. At rest, hyoscine hydrobromide was the only medication to increase pupil diameter and no drug intervention influenced blink rate. During performance of the cognitive task, hyoscine hydrobromide increased pupil diameter and promethazine increased blink rate. Promethazine was the only medication to influence the modified attention network test (ANT) by increasing the conflict effect and grand mean reaction time (RT). Pupil diameter and blink rate were both influenced by the central anticholinergics during performance of the cognitive test, thus highlighting the importance of central cholinergic pathways in the control of pupil diameter and blink rate. The collective effects of central anticholinergics on the modified ANT and on pupil diameter and blink rate during its performance, conveys the importance of central cholinergic pathways in cognitive function.
[Mh] Termos MeSH primário: Piscadela/efeitos dos fármacos
Antagonistas Colinérgicos/farmacologia
Cognição/efeitos dos fármacos
Pupila/efeitos dos fármacos
[Mh] Termos MeSH secundário: Atenção/efeitos dos fármacos
Atenção/fisiologia
Piscadela/fisiologia
Brometo de Butilescopolamônio/farmacologia
Sistema Nervoso Central/efeitos dos fármacos
Sistema Nervoso Central/metabolismo
Cognição/fisiologia
Estudos Cross-Over
Método Duplo-Cego
Feminino
Seres Humanos
Modelos Lineares
Masculino
Vias Neurais/efeitos dos fármacos
Vias Neurais/metabolismo
Testes Neuropsicológicos
Tamanho do Órgão
Prometazina/farmacologia
Pupila/fisiologia
Tempo de Reação/efeitos dos fármacos
Tempo de Reação/fisiologia
Descanso
Hidrobrometo de Escopolamina/farmacologia
Fatores de Tempo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholinergic Antagonists); 2Z3E1OF81V (Butylscopolammonium Bromide); 451IFR0GXB (Scopolamine Hydrobromide); FF28EJQ494 (Promethazine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160818
[St] Status:MEDLINE


  7 / 2237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27450607
[Au] Autor:Banting J; Meriano T
[Ti] Título:Sea State Green.
[So] Source:J Spec Oper Med;16(2):78-81, 2016.
[Is] ISSN:1553-9768
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The series objective is to review various clinical conditions/ presentations, including the latest evidence on management, and to dispel common myths. In the process, core knowledge and management principles are enhanced. A clinical case will be presented. Cases will be drawn from real life but phrased in a context that is applicable to the Special Operations Forces (SOF) or tactical emergency medical support (TEMS) environment. Details will be presented in such a way that the reader can follow along and identify how they would manage the case clinically depending on their experience and environment situation. Commentary will be provided by currently serving military medical technicians. The medics and author will draw on their SOF experience to communicate relevant clinical concepts pertinent to different operational environments including SOF and TEMS. Commentary and input from active special op.
[Mh] Termos MeSH primário: Acupressão/métodos
Antieméticos/uso terapêutico
Antagonistas Colinérgicos/uso terapêutico
Antagonistas de Dopamina/uso terapêutico
Antagonistas dos Receptores Histamínicos/uso terapêutico
Enjoo devido ao Movimento/prevenção & controle
[Mh] Termos MeSH secundário: Auxiliares de Emergência
Seres Humanos
Meclizina/uso terapêutico
Metoclopramida/uso terapêutico
Militares
Enjoo devido ao Movimento/fisiopatologia
Enjoo devido ao Movimento/terapia
Ondansetron/uso terapêutico
Prometazina/uso terapêutico
Hidrobrometo de Escopolamina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiemetics); 0 (Cholinergic Antagonists); 0 (Dopamine Antagonists); 0 (Histamine Antagonists); 3L5TQ84570 (Meclizine); 451IFR0GXB (Scopolamine Hydrobromide); 4AF302ESOS (Ondansetron); FF28EJQ494 (Promethazine); L4YEB44I46 (Metoclopramide)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170202
[Lr] Data última revisão:
170202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160725
[St] Status:MEDLINE


  8 / 2237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27318014
[Au] Autor:Kastner KW; Izaguirre JA
[Ad] Endereço:Department of Computer Science and Engineering, University of Notre Dame, Notre Dame, Indiana.
[Ti] Título:Accelerated molecular dynamics simulations of the octopamine receptor using GPUs: discovery of an alternate agonist-binding position.
[So] Source:Proteins;84(10):1480-9, 2016 Oct.
[Is] ISSN:1097-0134
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Octopamine receptors (OARs) perform key biological functions in invertebrates, making this class of G-protein coupled receptors (GPCRs) worth considering for insecticide development. However, no crystal structures and very little research exists for OARs. Furthermore, GPCRs are large proteins, are suspended in a lipid bilayer, and are activated on the millisecond timescale, all of which make conventional molecular dynamics (MD) simulations infeasible, even if run on large supercomputers. However, accelerated Molecular Dynamics (aMD) simulations can reduce this timescale to even hundreds of nanoseconds, while running the simulations on graphics processing units (GPUs) would enable even small clusters of GPUs to have processing power equivalent to hundreds of CPUs. Our results show that aMD simulations run on GPUs can successfully obtain the active and inactive state conformations of a GPCR on this reduced timescale. Furthermore, we discovered a potential alternate active-state agonist-binding position in the octopamine receptor which has yet to be observed and may be a novel GPCR agonist-binding position. These results demonstrate that a complex biological system with an activation process on the millisecond timescale can be successfully simulated on the nanosecond timescale using a simple computing system consisting of a small number of GPUs. Proteins 2016; 84:1480-1489. © 2016 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/química
Antagonistas de Receptores Adrenérgicos beta 2/química
Benzoxazinas/química
Simulação de Dinâmica Molecular
Prometazina/química
Propanolaminas/química
Receptores de Amina Biogênica/química
[Mh] Termos MeSH secundário: Gráficos por Computador
Ligações de Hidrogênio
Bicamadas Lipídicas/química
Fosfatidilcolinas/química
Ligação Proteica
Homologia Estrutural de Proteína
Termodinâmica
Fatores de Tempo
Interface Usuário-Computador
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Adrenergic beta-2 Receptor Antagonists); 0 (BI167107); 0 (Benzoxazines); 0 (Lipid Bilayers); 0 (Phosphatidylcholines); 0 (Propanolamines); 0 (Receptors, Biogenic Amine); 0 (norsynephrine receptor); 29PW75S82A (carazolol); FF28EJQ494 (Promethazine); TE895536Y5 (1-palmitoyl-2-oleoylphosphatidylcholine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170628
[Lr] Data última revisão:
170628
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160619
[St] Status:MEDLINE
[do] DOI:10.1002/prot.25091


  9 / 2237 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27315330
[Au] Autor:He LL; Wang ZX; Wang YX; Liu XP; Yang YJ; Gao YP; Wang X; Liu B; Wang X
[Ad] Endereço:College of Applied Chemistry, Shenyang University of Chemical Technology, Shenyang 110142, China.
[Ti] Título:Studies on the interaction between promethazine and human serum albumin in the presence of flavonoids by spectroscopic and molecular modeling techniques.
[So] Source:Colloids Surf B Biointerfaces;145:820-829, 2016 Sep 01.
[Is] ISSN:1873-4367
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Fluorescence, absorption, time-correlated single photon counting (TCSPC), and circular dichroism (CD) spectroscopic techniques as well as molecular modeling methods were used to study the binding characterization of promethazine (PMT) to human serum albumin (HSA) and the influence of flavonoids, rutin and baicalin, on their affinity. The results indicated that the fluorescence quenching mechanism of HSA by PMT is a static quenching due to the formation of complex. The reaction was spontaneous and mainly mediated by hydrogen bonds and hydrophobic interactions. The binding distance between the tryptophan residue of HSA and PMT is less than 8nm, which indicated that the energy transfer from the tryptophan residue of HSA to PMT occurred. The binding site of PMT on HSA was located in sites I and the presence of PMT can cause the conformational changes of HSA. There was the competitive binding to HSA between PMT and flavonoids because of the overlap of binding sites in HSA. The flavonoids could decrease the association constant and increase the binding distance. In addition, their synergistic effect can further change the conformation of HSA. The decrease in the affinities of PMT binding to HSA in the presence of flavonoids may lead to the increase of free drug in blood, which would affect the transportation or disposition of drug and evoke an adverse or toxic effect. Hence, rationalising dosage and diet regimens should be taken into account in clinical application of PMT.
[Mh] Termos MeSH primário: Flavonoides/química
Prometazina/química
Albumina Sérica/química
[Mh] Termos MeSH secundário: Dicroísmo Circular
Seres Humanos
Ligação Proteica
Rutina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Flavonoids); 0 (Serum Albumin); 347Q89U4M5 (baicalin); 5G06TVY3R7 (Rutin); FF28EJQ494 (Promethazine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170816
[Lr] Data última revisão:
170816
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160618
[St] Status:MEDLINE


  10 / 2237 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27189662
[Au] Autor:Singer AJ; Garra G; Thode HC
[Ad] Endereço:Department of Emergency Medicine, Stony Brook University, Stony Brook, New York.
[Ti] Título:Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective.
[So] Source:J Emerg Med;50(6):818-24, 2016 Jun.
[Is] ISSN:0736-4679
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Nausea and vomiting are common, but prevalence of antiemetic use in ED patients is unknown. OBJECTIVES: We determined the use of antiemetics in emergency department (ED) patients presenting with nausea and vomiting (NV). METHODS: We conducted a retrospective chart review of ED patients presenting to a local ED with NV and analyzed data from the National Hospital Ambulatory Care Survey for similar patients to determine the frequency of administration of antiemetics in the ED. RESULTS: Of 3876 patients presenting to a local ED with NV in 2014, 2637 (68% [95% confidence interval (CI) 67-69%]) received an antiemetic. Of an estimated 11.3 million U.S. ED visits for NV in 2011 (the latest year available), antiemetics were prescribed in 56% (95% CI 53-59%). Females, older patients, and those with vomiting were more likely to receive antiemetics. Use of antiemetics was associated with reduced admissions in the single institution (odds ratio [OR] 0.62, 95% CI 0.52-0.74), but not in the national database (OR 1.08, 95% CI 0.74-1.60). CONCLUSIONS: Many patients presenting with NV do not receive antiemetics while in the ED. Effort should be made to further study and reduce the phenomenon of undertreatment of nausea or vomiting, coined "oligoantiemesis."
[Mh] Termos MeSH primário: Antieméticos/uso terapêutico
Vômito/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Serviço Hospitalar de Emergência/organização & administração
Serviço Hospitalar de Emergência/normas
Feminino
Seres Humanos
Modelos Logísticos
Masculino
Metoclopramida/farmacologia
Metoclopramida/uso terapêutico
Náusea/tratamento farmacológico
Ondansetron/farmacologia
Ondansetron/uso terapêutico
Proclorperazina/farmacologia
Proclorperazina/uso terapêutico
Prometazina/farmacologia
Prometazina/uso terapêutico
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiemetics); 4AF302ESOS (Ondansetron); FF28EJQ494 (Promethazine); L4YEB44I46 (Metoclopramide); YHP6YLT61T (Prochlorperazine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160519
[St] Status:MEDLINE



página 1 de 224 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde